Table 2.
Clinical and laboratory characteristics at diagnosis of newly diagnosed pPCL patients, as reported in selected larger informative series of patients
Characteristic | Index | Values in NDMM | Newly diagnosed pPCL |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vela-Ojeda et al9 | Kraj et al52 | Tiedemann et al5 | Pagano et al51 | Garcia-Sanz et al6 | Costello et al49 | Colovic et al54 | Noel and Kyle7 | Avet-Loiseau et al13 | Woodruff et al53 | Dimopoulos et al8 | |||
No. of patients | 24 | 23 | 41 | 73 | 26 | 18 | 30 | 25 | 40 | 15 | 27 | ||
Clinical characteristics | |||||||||||||
Age, y | Median | 66-68 | 64 | 63 | 55 | — | 66 | 52 | 60 | 53 | 62 | 59 | 57 |
Male | % | 53-59 | 38 | 43 | 59 | 59 | 46 | 61 | 73 | 60 | — | 47 | — |
Durie-Salmon stage III | % | 50-60 | — | 85 | — | — | 92 | — | 87 | — | — | 87 | 96 |
ISS stage III | % | 26-34 | — | 80 | — | 78 | — | — | — | — | — | — | — |
Extramedullary plasmacytomas | % | 5-15 | — | — | 22 | 14 | 23 | 22 | 23 | — | — | — | — |
Splenomegaly | % | 1 | 21 | — | 18 | 18 | — | 28* | 53 | 44 | — | 53 | 26 |
Hepatomegaly | % | 4 | 25 | — | 32 | 23 | — | 28* | 57 | 52 | — | 73 | 7 |
Lymphadenopathy | % | 1 | 17 | — | 6 | 4 | — | 0 | 3 | 12 | — | 40 | 11 |
Bone disease | % | 79-81 | — | 67 | 35 | 64 | 48 | 61 | 60 | 44 | 59 | 67 | — |
Laboratory characteristics | |||||||||||||
PB plasmacytosis, × 109/L | Median | 0.003-0.0044 | 3.9 | — | 7.2 | 3.7 | — | 7.5 | 4.0 | 7.9 | 9.2 | 1.9 | — |
Range | 0-2.0 | 1.6-19.5 | — | 1.5-164 | 0.4-49.9 | — | 2.1-42 | 1.7-105 | 2.1-145.8 | 2.0-64 | 0.6-76.7 | — | |
White blood cells, × 109/L | Median | 5.8 | — | 15 | 21.5 | 13.7 | — | 24 | 16 | 19.7 | — | 14.5 | — |
Hemoglobin, g/dL | Median | 10.1-10.9 | — | — | 9.4 | 9.1 | 8.2 | 9 | 7.8 | 8.4 | — | 7.4 | — |
Platelets, × 109/L | Median | 209-242 | — | — | 98 | 116 | 123 | 62 | — | 94 | — | 112 | — |
Serum creatinine, mg/dL | Median | 1.2 | — | — | 1.9 | 1.7 | — | 1.5 | — | 2.6 | — | — | — |
≥ 2 mg/dL, % | 19-21 | 50 | 33 | — | 44 | 44 | 50† | 43‡ | — | — | 53 | 37 | |
Serum calcium, mg/dL | Median | 9.5-9.6 | — | — | 10 | 9.8 | — | 10 | — | 10.1 | — | 11.3 | — |
≥ 11 mg/dL, % | 13-20 | 37 | 52 | — | 27 | 48 | — | 60 | — | — | 60 | 44§ | |
β2-Microglobulin, mg/L | median | 3.6-3.9 | 10.4 | 8.4 | 6.8 | 8.5 | — | 6.0 | — | — | — | — | — |
≥ 6 mg/dL, % | 26-27 | — | — | — | — | 65 | 50 | 64 | — | — | — | 91 | |
Serum albumin, g/dL | median | 3.6 | — | 3.9 | — | 3.7 | — | — | 2.8 | — | — | — | — |
< 3.5 g/dL, % | 40 | — | 33 | — | 46 | 52 | — | — | — | — | — | — | |
Light-chain only | % | 10-20 | 21 | 19 | 41 | 41 | 31 | 28 | 20 | 50 | — | 40 | 26 |
BM plasmacytosis | Median | 40-50 | 90 | 80 | 78 | 80 | — | 76 | 80 | 84 | — | ≥ 70 | — |
Presenting features of patients with newly diagnosed myeloma (NDMM) are mainly derived from 3 large series of patients.5,6,99
— indicates not available; ISS, International Staging System; and PB, peripheral blood.
Splenomegaly and/or hepatomegaly.
Creatinine ≥ 1.4 mg/dL.
Creatinine ≥ 2.8 mg/dL.
Calcium > 11.5 mg/dL.